March 16, 2016
Although targeted therapies have shown great promise in the treatment of many cancers, they do not work on all patients. Researchers in the laboratories of KI members Doug Lauffenburger and Frank Gertler have discovered why a certain class of these drugs, kinase inhibitors, does not always halt tumor growth. Their identification of a biological “back-up system” to overcome the inhibition suggests a potential avenue for new combination therapies to improve the performance of kinase inhibitors in a clinical setting. Read more.